Crism Therapeutics (LSE:CRTX) Beta: 2.7336 (As of Jun. 30, 2026)


What is Crism Therapeutics Beta?

Crism Therapeutics LSE:CRTX -2.50% Beta is 2.7336 as of Jun. 30, 2026. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-30), Crism Therapeutics's Beta is 2.7336.

Crism Therapeutics  (LSE:CRTX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Crism Therapeutics Beta Related Terms

Crism Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Crism Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crism Therapeutics Beta Chart

Crism Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.09 1.38 0.00

Crism Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 0.23 1.38 -0.25 0.00

LSE:CRTX vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Crism Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crism Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crism Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Crism Therapeutics's Beta falls into.


Crism Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.7336 mean?
Crism Therapeutics (LSE:CRTX) has a Beta of 2.7336 as of Jun. 30, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Crism Therapeutics and its competitors.
Is Crism Therapeutics' Beta too high?
Crism Therapeutics' current Beta is 2.7336.
How does Crism Therapeutics' Beta compare to VRTX and REGN?
Crism Therapeutics' Beta of 2.7336 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Crism Therapeutics and its competitors. Crism Therapeutics's current Beta is 2.7336. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (LSE:CRTX) has a current Beta of 2.7336. The current Beta is 2.7336. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Crism Therapeutics (LSE:CRTX), the current Beta is 2.7336 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crism Therapeutics Business Description

Address Kingston Chambers, P.O. Box 173, Tortola, Road Town, VGB
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.